Repare Therapeutics Inc (RPTX)

$2.17 -0.05 (-2.03%)
Market Cap 95.21M
Revenue (ttm) 53.48M
Net Income (ttm) -84.69M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -158.36%
Debt to Equity Ratio 0.00
Volume 362,925
Avg Vol 580,330
Day's Range N/A - N/A
Shares Out 42.99M
Stochastic %K 83%
Beta 1.02
Analysts Sell
Price Target $3.00

Company Profile

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 412 7018
Address:
7171 Frederick-Banting, Building 2, Suite 270 St-Laurent, Montreal, Canada
OrientBeach
OrientBeach Dec. 6 at 5:08 PM
$RPTX Repare’s CMO, Maria Koehler once stated that she ‘ … believes the market for Camonsertib mono for NSCLC will be double ALK https://alk.lungevity.org/alk/about-alk-positive-lung-cancer# ALK currently accounts for 5% of all NSCLC cases, so If Repare was able to capture 75% of a ‘ … double ALK’ or 7.5% of all NSCLC cases that would give Repare a Net Present Value of $777,773,359 if commercialized by 2028 Camonsertib NSCLC ATMm NPV $1,555,546,719 Disc Finance Rate 30% Investment Cost ($150.0M) Yr 2 - ‘28 $2.413B Yr 3 - ‘29 $2.664B Yr 4 - ‘30 $2.941B Yr 5 - ‘31 $3.247B Assumption 1. The global NSCLC market was a $16.1B market in 2021 and has a CAGR of 10.104%. If Camonsertib is FDA approved in 2028 and captures 7.5% of the entire NSCLC global market Assumption 2. Repare’s Cost-of-Capital is 30% and this will be our NPV Discount Rate Assumption 3. A Global PII trial will cost $150.0M Conclusion: The above generated NPV would need to be cut in half to account for a 50% failed PIII rate
1 · Reply
Mnof
Mnof Dec. 3 at 8:52 AM
$RPTX Royalty aggregator companies like XOMA invest in a portfolio of assets across various stages of development and therapeutic areas to diversify risk https://xoma.com/ Focus is recently on early stage assets https://d1io3yog0oux5.cloudfront.net/_6775157bb00c1246490b5f9a03b34217/xoma/db/706/6250/pdf/11-25+November+2025+Corporate+Presentation+Distribution.pdf ie Repare. In Dec 2023 Xoma received $140M from funds managed by Blue Owl, which also holds 3.4m+ shares in Repare and recently agreed to vote these to aid ratification of the Xeno agreement https://ir.reparerx.com/news-releases/news-release-details/repare-therapeutics-enters-support-and-voting-agreements Repare needs 66.7% of shareholders to vote for the Xeno agreement https://ir.reparerx.com/news-releases/news-release-details/repare-therapeutics-enters-definitive-agreement-be-acquired Repare already secured voting shares of their BOD and their officers. Insiders hold 12,481,050 shares https://fintel.io/sn/us/rptx Votes secured from BVF partners LP holding 10,333,600 shares, Blue Owl 3,443,659 (see above) and OrbiMed holding 3,322,488 shares https://fintel.io/so/us/rptx from 13D/G and 13F filings. Combined = 29,580,797 (68.8%) from 42.986m outstanding. Xeno takeover passes without retail. Cash deliverables established courtesy of the CVR.
1 · Reply
UniversalTrading
UniversalTrading Nov. 28 at 12:43 PM
$RPTX Hmmm ..
0 · Reply
OrientBeach
OrientBeach Nov. 26 at 1:04 PM
$RPTX Fintel.io/ss/us/Rptx Short Shares Availability has increased by 1.7M shares, yet borrowing interest has increased to 6.88% - it had been 0.5% for months … its obvious there are many, many shorts in this company and it’s taking a while for them to all exit
0 · Reply
MoneyFollow
MoneyFollow Nov. 25 at 9:41 PM
$RPTX if this was the case, the share price would be rising, the lack of volume coupled with a lack of price movement means whoever is holding the shares is purposely keeping it down.
1 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 23 at 5:26 PM
$RPTX $RRC $RSPG $RSPT $RSVR
0 · Reply
OrientBeach
OrientBeach Nov. 23 at 3:03 PM
$RPTX There’s no doubt some tutes have left, namely Cathie’s Ark holdings of ~2.0m shares, but they seem to have been purchased by other tutes The core five remain intact, and the largest holdings own ~27.3M shares or 63.5% as of the final Q3 reporting date of November 14th - the same day Repare entered into a definitive arrangement agreement with Xeno Blue Owl - 3.4M BVF - 10.3M Acadian Asset. - 0.6M Orbimed - 3.3M Versant Ventures - 2.6M MPM Asset - 2.2M Rangley Capital - 0.6M Citadel Advisors - 0.7M Renaissance - 0.7M Red Mile - 1.6M Northern Trust - 1.3M Did these tutes not know of the pending acquisition?
1 · Reply
OrientBeach
OrientBeach Nov. 22 at 9:01 PM
$RPTX Even with BMS’ cost cutting measure of $1.5B now extended to the end of 2027, they have continued to work with Repare as evidence by the Sixth Amendment to Collaborate dated as recently as June 13th, 2025 https://ir.reparerx.com/static-files/9e07ce75-0368-48f4-8bec-c94b3f7849fb#page56 BMS now have in their possession four (4) drug target packages that Repare identified under their Agreement with BMS What is BMS going to do with the pending Xeno acquisition scheduled to close Q1 ‘26
0 · Reply
OrientBeach
OrientBeach Nov. 22 at 2:35 PM
$RPTX Excerpts taken from Repare’s Annual Report, 10-Q, over the last three (3) years; 2 “In October 2021, we received notification from BMS of their option exercise for two (2) druggable targets directed at a single synthetic lethal lesion . . . “ l. “In fiscal 2022, Bristol-Myers Squibb waived its rights to exercise options for druggable targets directed at two separate lesions” 2 “In fiscal 2023, BMS exercised its option for a druggable target and also waived its rights to exercise an option for another druggable target” 1 “In March 2024, BMS exercised its one remaining option to in-license an undruggable target for a combined total of five druggable targets and one undruggable target over the course of the collaboration To summarize, BMS exercised their option on three (3) targets and waived their rights to option exercise on three (3) targets. So is BMS preparing to in-license and start clinical trials on three drugs sometime soon?
1 · Reply
atkud
atkud Nov. 21 at 10:54 PM
$RPTX seriously what is happening with this company. Ive read everything and have no idea, as just your avg investor, to value this rt now
0 · Reply
Latest News on RPTX
Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.

Nov 20, 2025, 5:25 PM EST - 17 days ago

Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.

Halper Sadeh LLC Encourages RPTX and SEE Shareholders to Contact the Firm to Discuss Their Rights

Nov 18, 2025, 7:44 AM EST - 20 days ago

Halper Sadeh LLC Encourages RPTX and SEE Shareholders to Contact the Firm to Discuss Their Rights

SEE

Repare Therapeutics Agrees To Acquisition As Board Cites Best Path For Stakeholder Value

Nov 17, 2025, 10:24 AM EST - 21 days ago

Repare Therapeutics Agrees To Acquisition As Board Cites Best Path For Stakeholder Value

Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc.

Nov 14, 2025, 4:44 PM EST - 23 days ago

Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc.

Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 4:05 PM EDT - 7 weeks ago

Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Repare (RPTX) Q2 Loss Narrows 52%

Aug 8, 2025, 7:13 AM EDT - 4 months ago

Repare (RPTX) Q2 Loss Narrows 52%

Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 8, 2025, 7:00 AM EDT - 4 months ago

Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

Jul 15, 2025, 4:05 PM EDT - 5 months ago

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results

May 13, 2025, 4:05 PM EDT - 7 months ago

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results

Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

May 1, 2025, 7:00 AM EDT - 7 months ago

Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

May 1, 2025, 7:00 AM EDT - 7 months ago

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

Apr 25, 2025, 1:00 PM EDT - 8 months ago

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

Repare Therapeutics Announces Leadership Transitions

Mar 31, 2025, 4:39 PM EDT - 8 months ago

Repare Therapeutics Announces Leadership Transitions

Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 7, 2025, 4:05 PM EST - 9 months ago

Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 7:05 AM EST - 10 months ago

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

Jan 9, 2025, 4:05 PM EST - 11 months ago

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

Why Is Repare Therapeutics Stock Trading Lower On Friday?

Dec 13, 2024, 12:09 PM EST - 1 year ago

Why Is Repare Therapeutics Stock Trading Lower On Friday?

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Dec 12, 2024, 4:20 PM EST - 1 year ago

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

Dec 10, 2024, 4:05 PM EST - 1 year ago

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib

Nov 12, 2024, 7:05 AM EST - 1 year ago

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 7:05 AM EST - 1 year ago

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial

Oct 23, 2024, 6:05 AM EDT - 1 year ago

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor

Oct 14, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor

Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting

Sep 30, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting

Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers

Sep 23, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers

Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024

Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data

Aug 30, 2024, 6:13 PM EDT - 1 year ago

Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data

Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio

Aug 28, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio

Repare Therapeutics to Participate in Two Upcoming Investor Conferences

Aug 27, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics to Participate in Two Upcoming Investor Conferences

Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results

Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI

Jun 26, 2024, 10:30 AM EDT - 1 year ago

Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI

Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib

Jun 12, 2024, 7:00 AM EDT - 1 year ago

Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib

Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial

Jun 10, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial

Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer

Jun 4, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer

Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 3, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024

May 29, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results

May 7, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results

Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition

Apr 30, 2024, 7:05 AM EDT - 1 year ago

Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition

Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition

Apr 30, 2024, 7:05 AM EDT - 1 year ago

Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition

Repare Therapeutics Appoints Steven H. Stein, M.D.

Apr 26, 2024, 4:05 PM EDT - 1 year ago

Repare Therapeutics Appoints Steven H. Stein, M.D.

Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Mar 21, 2024, 10:00 AM EDT - 1 year ago

Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 28, 2024, 7:05 AM EST - 1 year ago

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664

Feb 15, 2024, 7:05 AM EST - 1 year ago

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664

OrientBeach
OrientBeach Dec. 6 at 5:08 PM
$RPTX Repare’s CMO, Maria Koehler once stated that she ‘ … believes the market for Camonsertib mono for NSCLC will be double ALK https://alk.lungevity.org/alk/about-alk-positive-lung-cancer# ALK currently accounts for 5% of all NSCLC cases, so If Repare was able to capture 75% of a ‘ … double ALK’ or 7.5% of all NSCLC cases that would give Repare a Net Present Value of $777,773,359 if commercialized by 2028 Camonsertib NSCLC ATMm NPV $1,555,546,719 Disc Finance Rate 30% Investment Cost ($150.0M) Yr 2 - ‘28 $2.413B Yr 3 - ‘29 $2.664B Yr 4 - ‘30 $2.941B Yr 5 - ‘31 $3.247B Assumption 1. The global NSCLC market was a $16.1B market in 2021 and has a CAGR of 10.104%. If Camonsertib is FDA approved in 2028 and captures 7.5% of the entire NSCLC global market Assumption 2. Repare’s Cost-of-Capital is 30% and this will be our NPV Discount Rate Assumption 3. A Global PII trial will cost $150.0M Conclusion: The above generated NPV would need to be cut in half to account for a 50% failed PIII rate
1 · Reply
Mnof
Mnof Dec. 3 at 8:52 AM
$RPTX Royalty aggregator companies like XOMA invest in a portfolio of assets across various stages of development and therapeutic areas to diversify risk https://xoma.com/ Focus is recently on early stage assets https://d1io3yog0oux5.cloudfront.net/_6775157bb00c1246490b5f9a03b34217/xoma/db/706/6250/pdf/11-25+November+2025+Corporate+Presentation+Distribution.pdf ie Repare. In Dec 2023 Xoma received $140M from funds managed by Blue Owl, which also holds 3.4m+ shares in Repare and recently agreed to vote these to aid ratification of the Xeno agreement https://ir.reparerx.com/news-releases/news-release-details/repare-therapeutics-enters-support-and-voting-agreements Repare needs 66.7% of shareholders to vote for the Xeno agreement https://ir.reparerx.com/news-releases/news-release-details/repare-therapeutics-enters-definitive-agreement-be-acquired Repare already secured voting shares of their BOD and their officers. Insiders hold 12,481,050 shares https://fintel.io/sn/us/rptx Votes secured from BVF partners LP holding 10,333,600 shares, Blue Owl 3,443,659 (see above) and OrbiMed holding 3,322,488 shares https://fintel.io/so/us/rptx from 13D/G and 13F filings. Combined = 29,580,797 (68.8%) from 42.986m outstanding. Xeno takeover passes without retail. Cash deliverables established courtesy of the CVR.
1 · Reply
UniversalTrading
UniversalTrading Nov. 28 at 12:43 PM
$RPTX Hmmm ..
0 · Reply
OrientBeach
OrientBeach Nov. 26 at 1:04 PM
$RPTX Fintel.io/ss/us/Rptx Short Shares Availability has increased by 1.7M shares, yet borrowing interest has increased to 6.88% - it had been 0.5% for months … its obvious there are many, many shorts in this company and it’s taking a while for them to all exit
0 · Reply
MoneyFollow
MoneyFollow Nov. 25 at 9:41 PM
$RPTX if this was the case, the share price would be rising, the lack of volume coupled with a lack of price movement means whoever is holding the shares is purposely keeping it down.
1 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 23 at 5:26 PM
$RPTX $RRC $RSPG $RSPT $RSVR
0 · Reply
OrientBeach
OrientBeach Nov. 23 at 3:03 PM
$RPTX There’s no doubt some tutes have left, namely Cathie’s Ark holdings of ~2.0m shares, but they seem to have been purchased by other tutes The core five remain intact, and the largest holdings own ~27.3M shares or 63.5% as of the final Q3 reporting date of November 14th - the same day Repare entered into a definitive arrangement agreement with Xeno Blue Owl - 3.4M BVF - 10.3M Acadian Asset. - 0.6M Orbimed - 3.3M Versant Ventures - 2.6M MPM Asset - 2.2M Rangley Capital - 0.6M Citadel Advisors - 0.7M Renaissance - 0.7M Red Mile - 1.6M Northern Trust - 1.3M Did these tutes not know of the pending acquisition?
1 · Reply
OrientBeach
OrientBeach Nov. 22 at 9:01 PM
$RPTX Even with BMS’ cost cutting measure of $1.5B now extended to the end of 2027, they have continued to work with Repare as evidence by the Sixth Amendment to Collaborate dated as recently as June 13th, 2025 https://ir.reparerx.com/static-files/9e07ce75-0368-48f4-8bec-c94b3f7849fb#page56 BMS now have in their possession four (4) drug target packages that Repare identified under their Agreement with BMS What is BMS going to do with the pending Xeno acquisition scheduled to close Q1 ‘26
0 · Reply
OrientBeach
OrientBeach Nov. 22 at 2:35 PM
$RPTX Excerpts taken from Repare’s Annual Report, 10-Q, over the last three (3) years; 2 “In October 2021, we received notification from BMS of their option exercise for two (2) druggable targets directed at a single synthetic lethal lesion . . . “ l. “In fiscal 2022, Bristol-Myers Squibb waived its rights to exercise options for druggable targets directed at two separate lesions” 2 “In fiscal 2023, BMS exercised its option for a druggable target and also waived its rights to exercise an option for another druggable target” 1 “In March 2024, BMS exercised its one remaining option to in-license an undruggable target for a combined total of five druggable targets and one undruggable target over the course of the collaboration To summarize, BMS exercised their option on three (3) targets and waived their rights to option exercise on three (3) targets. So is BMS preparing to in-license and start clinical trials on three drugs sometime soon?
1 · Reply
atkud
atkud Nov. 21 at 10:54 PM
$RPTX seriously what is happening with this company. Ive read everything and have no idea, as just your avg investor, to value this rt now
0 · Reply
Logan12071
Logan12071 Nov. 20 at 10:38 PM
$RPTX anyone seen the new PR
0 · Reply
john116868
john116868 Nov. 20 at 3:40 PM
$RPTX pos
0 · Reply
StockScanners
StockScanners Nov. 19 at 3:55 AM
$RPTX reached 2.30
0 · Reply
BiotechBonesaw
BiotechBonesaw Nov. 18 at 8:04 PM
$RPTX congratulations on the buyout! 💪
0 · Reply
sn0wball
sn0wball Nov. 18 at 6:53 PM
$RPTX can't buy any dips :) what's this worth when all is done and how long?
0 · Reply
DinoTradez
DinoTradez Nov. 18 at 5:57 PM
$RPTX Good morning everyone! 🥂
0 · Reply
TraderJay85
TraderJay85 Nov. 18 at 4:56 PM
$RPTX about to break. 🔥
1 · Reply
john116868
john116868 Nov. 18 at 2:58 PM
$RPTX should of took L on calls yesterday fucking bagged
0 · Reply
Mnof
Mnof Nov. 18 at 1:05 PM
$RPTX Inflection points for future value ie CVR https://ir.reparerx.com/news-releases/news-release-details/repare-therapeutics-enters-definitive-agreement-be-acquired -Lunresertib (Lun) now Debio 2513 (RP-6306) https://www.debiopharm.com/pipeline/lunresertib-debio-2513/ Current Mythic trial Lun + Debio 0123 phase (Ph)1/1b, recruiting, has primary completion (pc) end June 2026, 90% of net proceeds, first 2 yrs. Also, https://clinicaltrials.gov/study/NCT04855656 being evaluated in a Ph2 by the Canadian Cancer Trials Group, active and primary completion (pc) expected Dec 2025 https://clinicaltrials.gov/study/NCT05605509 If Debiopharm decides to perform Ph2b/3 would add 90% net proceed. Ph1 (POLAR) with RP-3467 currently active https://clinicaltrials.gov/study/NCT06560632 pc Oct 2026, would likely be outside 90d, license around Q3, subject to 50% net proceeds. Ph2 for Camonsertib (RP-3500) currently recruiting https://www.clinicaltrials.gov/study/NCT05566574 changed pc recently, was Oct 2025 now end Sept 2026. Disposition is on the cards if results same as Ph1 https://stocktwits.com/Mnof/message/627157474 again subject to 50% net proceeds as disposition expected Q3/4. BMS-decision to move any target into IND creates value.
1 · Reply
AVCTQBNAPL
AVCTQBNAPL Nov. 18 at 8:41 AM
$CLIK $NOTV $RPTX $RYET $SGBX
0 · Reply
PaulLaurent
PaulLaurent Nov. 18 at 6:34 AM
🌅 4:00am EST Watchlist $RYET – Commercial release of CogniAI. Watch first deployments, pricing model, enterprise pilots, and early KPI traction; look for follow-on contracts. $NOTV – Prelim Q4/FY25 out. Focus on revenue/margin cadence, guidance color, restructuring updates, balance-sheet runway, and any FY26 setup. $CLIK – Announced strategic acquisitions to expand capabilities. Track integration timeline, revenue mix impact, cost synergies, and any share/financing mechanics. $RPTX – Potential multi-day runner. Favor VWAP holds, liquidity expansion, and clean pullback entries. $SGBX – Potential multi-day runner. Look for higher-low structure, volume persistence, and catalyst follow-through. Tone: Product launches, prelim results, and M&A headlines lead. Favor VWAP/pivot reclaims, trim into strength, keep risk tight.
0 · Reply
Thess5
Thess5 Nov. 17 at 11:54 PM
$ADAPY Tead today’s article. The BOD has all left except for a few. New CEO, like the man said restructuring complete. 2026 plans in place. We could see %200 tomorrow let alone the 50% + today!!! Up over 100% total on trades here already! $GPUS 👇🏽👇🏽👇🏽 trades! $ICU ✅ 👍👍👍trades $RPTX 🔍 $QUBT ✅ 👍trade!
0 · Reply